1. Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer
- Author
-
Laura Cato, Antje Neeb, Adam Sharp, Victor Buzón, Scott B Ficarro, Linxiao Yang, Claudia Muhle-Goll, Nane C Kuznik, Ruth Riisnaes, Daniel Nava Rodrigues, Olivier Armant, Victor Gourain, Guillaume Adelmant, Emmanuel A Ntim, Thomas Westerling, David Dolling, Pasquale Rescigno, Ines Figueiredo, Friedrich Fauser, Jennifer Wu, Jaice T Rottenberg, Liubov Shatkina, Claudia Ester, Burkhard Luy, Holger Puchta, Jakob Troppmair, Nicole Jung, Stefan Bräse, Uwe Strähle, Jarrod A Marto, Gerd Ulrich Nienhaus, Bissan Al-Lazikani, Xavier Salvatella, Johann S de Bono, Andrew CB Cato, and Myles Brown
- Subjects
prostate cancer ,androgen receptor ,Bag-1L ,transcription factors ,Medicine ,Science ,Biology (General) ,QH301-705.5 - Abstract
Targeting the activation function-1 (AF-1) domain located in the N-terminus of the androgen receptor (AR) is an attractive therapeutic alternative to the current approaches to inhibit AR action in prostate cancer (PCa). Here we show that the AR AF-1 is bound by the cochaperone Bag-1L. Mutations in the AR interaction domain or loss of Bag-1L abrogate AR signaling and reduce PCa growth. Clinically, Bag-1L protein levels increase with progression to castration-resistant PCa (CRPC) and high levels of Bag-1L in primary PCa associate with a reduced clinical benefit from abiraterone when these tumors progress. Intriguingly, residues in Bag-1L important for its interaction with the AR AF-1 are within a potentially druggable pocket, implicating Bag-1L as a potential therapeutic target in PCa.
- Published
- 2017
- Full Text
- View/download PDF